Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Abstract

Background Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease. Methods We did this randomised, double-blind, placebo-controlled study at 38 hospitals in 19 countries worldwide. We enrolled HIV-negative and human herpesvirus-8-seronegative patients with symptomatic multicentric Castleman's disease. Treatment allocation was randomised with a computer-generated list, with block size six, and stratification by baseline corticosteroid use. Patients and investigators were masked to treatment allocation. Patients were randomly assigned (2:1) to siltuximab (11 mg/kg intravenous infusion every 3 weeks) or placebo; all patients also received best supportive care. Patients continued treatment until treatment failure. The primary endpoint was durable tumour and symptomatic response for at least 18 weeks for the intention-to-treat population. Enrolment has been completed. The study is registered with ClinicalTrials.gov, number NCT01024036. Findings We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symptomatic responses occurred in 18 (34%) of 53 patients in the siltuximab group and none of 26 in the pla…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)70319-5

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Castleman, 1954, Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C Cabot, N Engl J Med, 251, 396

Cited by

See all 454

Metadata

Authors
van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., Goh, Y. T., Zhu, J., Cho, S.-G., Ren, H., Cavet, J., Bandekar, R., Rothman, M., Puchalski, T. A., Reddy, M., van de Velde, H., Vermeulen, J., & Casper, C.
Affiliations
  • Chinese University of Hong Kong (HK)
  • Dana-Farber Cancer Institute (US)
  • Oslo University Hospital (NO)
  • North Shore Hospital (NZ)
  • Hospital Mãe de Deus (BR)
  • Sichuan University (CN)
  • Mackay Memorial Hospital (TW)
  • Singapore General Hospital (SG)
  • Peking University Cancer Hospital (CN)
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
  • Peking University First Hospital (CN)
  • University of Manchester (GB)
  • Janssen Research & Development (United States) (US)
  • Janssen (Netherlands) (NL)
  • Fred Hutch Cancer Center (US)
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2014-08
Volume
15
Issue
9
Pages
966-974
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2169031812
Cited by
454
References
24
Citations by year
2026: 37 · 2025: 32 · 2024: 36 · 2023: 33 · 2022: 56 · 2021: 39 · 2020: 45 · 2019: 21 · 2018: 41 · 2017: 40 · 2016: 29 · 2015: 38 · 2014: 5
FWCI
18.00
Type
journal article
Language
en
Update notices
erratum (2014-09-01)
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Janssen Research and Development
Topics
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphadenopathy Diagnosis and Analysis
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
multicentric Castleman disease, siltuximab, interleukin-6, chimeric monoclonal antibody, lymphoproliferative disorders, tumor response, adverse events, HIV-negative patients, human herpesvirus 8, corticosteroid use, fatigue, anemia, night sweats, treatment duration, best supportive care, comparative efficacy and safety
MeSH terms
Adult, Aged, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Castleman Disease, Humans, Infusions, Intravenous, International Cooperation, Male, Middle Aged, Reference Values, Severity of Illness Index, Survival Rate, Confidence Intervals, Treatment Outcome, Risk Assessment, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(14)70319-5
The paper
van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., Goh, Y. T., Zhu, J., Cho, S.-G., Ren, H., Cavet, J., Bandekar, R., Rothman, M., Puchalski, T. A., Reddy, M., . . . Casper, C. (2014). Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)70319-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.